台灣版糖尿病生活品質測量工具Diabetes-39的發展與驗證

Development and Validation of a Chinese Version of the diabetes-39 to Measure Diabetes Quality of Life in Taiwan

10.6288/TJPH2009-28-03-06

黃情川(Chyng-Chuang Hwang)；黃一展(I-Chan Huang)；吳明彥(Ming-Yen Wu)；陳姿君(Tzu-Chun Chen)；吳菁珍(Jing-Jhen Wu)；林文德(Wen-Der Lin)

糖尿病 ； 生活品質 ； Diabetes-39台灣版 ； 心理計量 ； Diabetes Mellitus ； Quality of life ； D-39 Chinese version ； psychometric property

台灣公共衛生雜誌

28卷3期（2009 / 06 / 01）

218 - 231

繁體中文

目標：進行糖尿病生活品質測量工具D-39中文版的翻譯及驗證。方法：橫斷式研究法。對象為署立台南醫院糖尿病門診病患280人。資料收集為病人問卷與病歷摘要。病歷摘要收集臨床變項用以驗證D-39，包括實驗室診斷（醣化血色素、飯前與飯後2小時血糖）與糖尿病併發症（視網膜病變、腎臟病變、神經病變、足部病變、心血管疾病、及腦血管疾病）。心理計量分析包括信度與效度。結果：翻譯結果顯示，中文版D-39在語意上與英文版相似，且能被病人接受。心理計量分析發現，D-39中文版的測量結構與英文版相吻合。D-39與SF-36（效標）同質性面向之相關性較異質性面向強。D-39對於飯後2小時血糖及肌酸酐等指標，及心血管疾病、腦血管疾病、與足部病變等併發症，分別呈現有意義的預知組別效度（效果量＞0.2）。D-39對於神經病變、腦血管疾病、視網膜病變、足部病變、心血管疾病、與腎臟病變的綜合鑑別效度達到可接受的標準（C-統計值＞0.7）。結論：本研究翻譯並驗證了中文版D-39，其結果將有助於糖尿病人健康結果之評估。

Objectives: The Diabetes-39 (D-39) is a well-validated and widely used diabetes quality of life (QOL) instrument. The purpose of this study was to translate the D-39 into Chinese and test its psychometric properties. Methods: Data were collected from 280 patients treated in diabetes clinics of the Tainan Hospital, Taiwan Department of Health, through QOL survey and medical record review. Information collected from medical records, used to validate the D-39, included laboratory indicators (hemoglobin A1c (HbA1c), fasting plasma glucose, 2-hour postprandial plasma glucose (2-h PPG), creatinine (Cr), and glomerular filtration rate) and diabetes complications (retinopathy, nephropathy, neuropathy, diabetic foot complications, cardiovascular complications, and cerebrovascular complications). We conducted forward/back translations and a focus group session to develop the Chinese version of the instrument. For psychometric evaluation, we analyzed construct validity, convergent/discriminant validity (using the SF-36 as the standard), known-group validity, and overall discriminant validity of the D-39. Results: The D-39 Chinese version demonstrated equivalent semantics to the original D-39. Pearson's correlations were weak with subscales measuring heterogeneous constructs between the D-39 and SF-36, but high among subscales measuring homogenous constructs, suggesting good convergent/discriminant validity. The D-39 discriminated better for 2-h PPG, Cr, cardiovascular, cerebrovascular, and diabetic foot complications (effect size ＞0.2), suggesting good knowngroup validity. C-indexes suggested greater discrimination (＞0.7) by the D-39 compared to the SF-36 across all complications, indicating good overall discriminate validity. Conclusions: Our successfully translated D-39 demonstrated good psychometric properties. The D-39 Chinese version is an acceptable instrument for assessing treatment effectiveness and monitoring patient outcomes in Taiwan.

1. Huang MC,Hung CH.(2007).Quality of life and its predictors for middle-aged and elderly patients with type 2 diabetes mellitus.J Nurs Res,15,193-201.
   連結：
2. Lu JF,Tseng HM,Tsai YJ.(2003).Assessment of healthrelated quality of life in Taiwan (I): development and psychometric testing of SF-36 Taiwan version.Taiwan J Public Health,22,501-511.
   連結：
3. American Diabetes Association(2007).Standards of medical care in diabetes-2007.Diabetes Care,30,4-41.
4. Anderson RM,Fitzgerald JT,Wisdom K,Davis WK,Hiss RG.(1997).A comparison of global versus diseasespecific quality-of-life measures in patients with NIDDM.Diabetes Care,20,299-305.
5. Arauz-Pacheco C,Parrott MA,Raskin P,American Diabetes Association(2003).Treatment of hypertension in adults with diabetes.Diabetes Care,26,80-582.
6. Berzon R,Hays RD,Shumaker SA.(1993).International use, application and performance of health-related quality of life instruments.Qual Life Res,2,367-368.
7. Bonora E,Muggeo M.(2001).Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence.Diabetologia,44,2107-2114.
8. Boyer JG,Earp JA.(1997).The development of an instrument for assessing the quality of life of people with diabetes. Diabetes-39.Med Care,35,440-453.
9. Cavalit F,Petrelli A,Traversa M(2006).Postprandial blood glucose is a stronger predictor of cardiovascular events than fast blood glucose in type 2 diabetes mellitus, particularly in women: lesions from the San Luigi Gonzaga Diabetes Study.J Clin Endocrinol Metab,91,813-819.
10. Ceriello A.(2005).Postprandial hyperglycemia and diabetes complications: is it time to treat?.Diabetes,54,1-7.
11. Chobanian AV,Bakris GL,Black HR(2003).The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.JAMA,289,2560-2572.
12. Crosby RD,Kolotkin RL,Williams GR.(2003).Defining clinically meaningful change in health-related quality of life.J Clin Epidemiol,56,395-407.
13. de Vet HC,Ader HJ,Terwee CB,Pouwer F.(2005).Are factor analytical techniques used appropriately in the validation of health status questionnaires? A systematic review on the quality of factor analysis of the SF-36.Qual Life Res,14,1203-1224.
14. Garratt AM,Schmidt L,Fitzpatrick R.(2002).Patientassessed health outcome measures for diabetes: a structured review.Diabet Med,19,1-11.
15. Gerich JE.(2003).Clinical significance, pathogenesis, and management of postprandial hyperglycemia.Arch Intern Med,163,1306-1316.
16. Gill TM,Feinstein AR.(1994).A critical appraisal of the quality of quality-of-life measurements.JAMA,272,619-626.
17. Glasgow RE,Ruggiero L,Eakin EG,Dryfoos J,Chobanian L.(1997).Quality of life and associated characteristics in a large national sample of adults with diabetes.Diabetes Care,20,562-567.
18. Goddijn P,Bilo H,Meadows K,Groenier K,Feskens E,Meyboom-de Jong B.(1996).The validity and reliability of the Diabetes Health Profile (DHP) in NIDDM patients referred for insulin therapy.Qual Life Res,5,433-442.
19. Hahl J,Hämäläinen H,Sintonen H,Simell T,Arinen S,Simell O.(2002).Health-related quality of life in type 1 diabetes without or with symptoms of long-term complications.Qual Life Res,11,427-436.
20. Hanley JA,McNeil BJ.(1983).A method of comparing the areas under receiver operating characteristic curves derived from the same cases.Radiology,148,839-843.
21. Hanley JA,McNeil BJ.(1982).The meaning and use of the area under a receiver operating characteristic (ROC) curve.Radiology,143,29-36.
22. Jacobson AM,de Groot M,Samson JA.(1994).The evaluation of two measures of quality of life in patients with type I and type II diabetes.Diabetes Care,17,267-274.
23. Johnson JA,Maddigan SL.(2004).Performance of the RAND-12 and SF-12 summary scores in type 2 diabetes.Qual Life Res,13,449-456.
24. Kasper DL,Braunwald E,Hauser S(2004).Harrison's Principles of Internal Medicine.New York:McGraw-Hill Professional.
25. Li TC,Lee YD,Lin CC,Amidon RL.(2004).Quality of life of primary caregivers of elderly with cerebrovascular disease or diabetes hospitalized for acute care: assessment of well-being and functioning using the SF-36 health questionnaire.Qual Life Res,13,1081-1088.
26. Li TC,Lin CC,Liu CS,Li CI,Lee YD.(2006).Validation of the Chinese version of the diabetes impact measurement scales amongst people suffering from diabetes.Qual Life Res,15,1613-1619.
27. Lloyd CE,Mattews KA,Wing RR,Orchard TJ.(1992).Psychosocial factors and complications of IDDM. The Pittsburgh Epidemiology of Diabetes Complications Study. VIII.Diabetes Care,15,166-172.
28. Maddigan SL,Feeny DH,Johnson JA,DOVE Investigators.(2004).Construct validity of the RAND-12 and Health Utilities Index Mark 2 and 3 in type 2 diabetes.Qual Life Res,13,435-448.
29. National Kidney Foundation(2002).K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.Am J Kidney Dis,39,1-266.
30. Naughton MJ,Shumaker SA.(2003).The case for domains of function in quality of life assessment.Qual Life Res,12,73-80.
31. Nunnally JC,Bernstein IH.(1994).Psychometric Theory.New York:McGraw-Hill.
32. Revicki DA,Osoba D,Fairclough D(2000).Recommendations on health-related quality of life to support labeling and promotional claims in the United States.Qual Life Res,9,887-900.
33. Rijken M,van Kerkhof M,Dekker J,Schellevis FG.(2005).Comorbidity of chronic diseases: effects of disease pairs on physical and mental functioning.Qual Life Res,14,45-55.
34. Saito I,Inami F,Ikebe T(2006).Impact of diabetes on health-related quality of life in a population study in Japan.Diabetes Res Clin Pract,73,51-57.
35. Testa MA,Simonson DC.(1998).Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial.JAMA,208,1490-1496.
36. Testa MA,Simonson DC,Turner RR.(1998).Valuing quality of life and improvements in glycemic control in people with type 2 diabetes.Diabetes Care,21,44-52.
37. The Diabetes Control and Complications Trial(1995).The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial.Diabetes,44,968-983.
38. UK Prospective Diabetes Study Group(1999).Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37).Diabetes Care,22,1125-1136.
39. Watkins K,Connell CM.(2004).Measurement of healthrelated QOL in diabetes mellitus.Pharmacoeconomics,22,1109-1126.
40. Wei JN,Chuang LM,Lin RS,Chao CL,Sung FC.(2000).Prevalence and hospitalization rates of diabetes mellitus in Taiwan.J Public Health,21,173-180.
41. Wikblad K,Leksell J,Wibell L.(1996).Health-related quality of life in relation to metabolic control and late complications in patients with insulin dependent diabetes mellitus.Qual Life Res,5,123-130.
42. Wild D,Grove A,Martin M(2005).Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation.Value Health,8,94-104.
43. World Health Organization Quality of Life Group(1982).The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization, 1995b.Soc Sci Med,41,1403-1409.